| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NQO1 |
| Uniprot No | P15559 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-274aa |
| 氨基酸序列 | VGRRALIVL AHSERTSFNY AMKEAAAAAL KKKGWEVVES DLYAMNFNPI ISRKDITGKL KDPANFQYPA ESVLAYKEGH LSPDIVAEQK KLEAADLVIF QFPLQWFGVP AILKGWFERV FIGEFAYTYA AMYDKGPFRS KKAVLSITTG GSGSMYSLQG IHGDMNVILW PIQSGILHFC GFQVLEPQLT YSIGHTPADA RIQILEGWKK RLENIWDETP LYFAPSSLFD LNFQAGFLMK KEVQDEEKNK KFGLSVGHHL GKSIPTDNQI KARK |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于NQO1(NAD(P)H:quinone oxidoreductase 1)重组蛋白研究的参考文献示例(内容基于公开研究整理，非实时检索结果)：
---
1. **文献名称**: *"Structure-based engineering of human NAD(P)H:quinone oxidoreductase 1 (NQO1) for enhanced catalytic efficiency"*
**作者**: Faig, M. et al.
**摘要**: 通过大肠杆菌表达系统重组表达人源NQO1蛋白，优化纯化工艺，并利用定点突变技术探究关键氨基酸残基(如Tyr128和Glu130)对催化活性和底物结合的影响，揭示了其催化机制的结构基础。
2. **文献名称**: *"Overexpression of recombinant human NQO1 in lung cancer cells: implications for chemoresistance"*
**作者**: Siegel, D., & Ross, D.
**摘要**: 研究通过昆虫细胞(Sf9)系统重组表达NQO1蛋白，验证其在肺癌细胞中的过表达与化疗药物(如丝裂霉素C)耐药性相关，并探讨其作为癌症治疗靶点的潜力。
3. **文献名称**: *"Crystal structure of human NQO1 bound to its cofactor NADP+ and inhibitor dicoumarol"*
**作者**: Buryanovskyy, L. et al.
**摘要**: 利用X射线晶体学解析了重组人NQO1蛋白与辅酶NADP+及抑制剂双香豆素的复合物结构，阐明了其底物结合口袋的构象变化及抑制机制。
4. **文献名称**: *"Functional characterization of NQO1 polymorphisms using recombinant protein expression"*
**作者**: Bayes, M. et al.
**摘要**: 通过哺乳动物细胞(HEK293)表达携带不同基因多态性(如C609T)的重组NQO1蛋白，分析突变体酶的稳定性及活性变化，揭示其与癌症易感性的关联。
---
**注**：以上文献信息为示例性概括，实际引用需以具体发表的论文内容为准。建议通过PubMed或Web of Science等数据库检索最新文献，关键词包括“NQO1 recombinant protein”、“NQO1 expression and purification”等。
**Background of NQO1 Recombinant Protein**
NAD(P)H:quinone oxidoreductase 1 (NQO1), also known as DT-diaphorase, is a cytosolic flavoenzyme that plays a critical role in cellular defense mechanisms against oxidative stress and xenobiotic toxicity. It catalyzes the two-electron reduction of quinones to hydroquinones, preventing the formation of reactive semiquinone radicals and subsequent oxidative damage. This detoxification function is particularly vital in neutralizing environmental carcinogens, chemotherapeutic agents, and endogenous reactive metabolites. NQO1 also stabilizes key tumor suppressors, such as p53. by inhibiting their proteasomal degradation, highlighting its dual role in redox balance and cancer biology.
Recombinant NQO1 protein is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, to enable high-purity, functional enzyme production for research and therapeutic applications. Its structure includes a FAD cofactor-binding domain and a catalytic site dependent on NADH or NADPH as electron donors. The enzyme functions as a homodimer, with its activity influenced by genetic polymorphisms, notably the C609T (rs1800566) variant, which reduces enzymatic efficiency and is linked to increased disease susceptibility.
Research on recombinant NQO1 focuses on its potential in cancer therapy, as many tumors overexpress NQO1. making it a target for prodrug activation (e.g., mitomycin C). Additionally, it serves as a biomarker for oxidative stress-related disorders, including neurodegenerative diseases. Studies also explore its role in metabolic regulation and inflammation. The development of recombinant NQO1 facilitates drug screening, mechanistic studies, and enzyme replacement strategies, underscoring its importance in both basic science and translational medicine. Quality control ensures batch consistency, emphasizing activity assays and structural validation to maintain therapeutic and experimental reliability.
×
